Related Experiment Video
Updated: Mar 31, 2026
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
Published on: February 1, 2020
Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study
Hiroshi Imaoka1, Nobumasa Mizuno, Kazuo Hara
1From the Departments of *Gastroenterology and †Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Objectives:
The modified Glasgow prognostic score (mGPS) is known to be useful in determining the prognosis of cancers. However, the utility of mGPS for pancreatic cancer (PC) has been examined based primarily on a surgical series of early-stage cancers. The purpose of this study was to examine the utility of mGPS for PC of all stages using a retrospective cohort design.
Methods:
We conducted a retrospective cohort study using data from a computerized database. A total of 807 patients with pathologically confirmed PC were analyzed (mGPS-0, n = 620; mGPS-1, n = 153; mGPS-2, n = 34).
Results:
Median overall survival (OS) was significantly worse for the mGPS-1 group than for the mGPS-0 group (5.8 vs 15.8 months, respectively) but was comparable between the mGPS-2 and mGPS-1 groups (4.8 vs 5.8 months, respectively). After adjustment, both mGPS-1 and mGPS-2 were independent predictive factors of OS (mGPS-1: hazard ratio, 1.772; 95% confidence interval, 1.417-2.215; mGPS-2: hazard ratio, 2.033; 95% confidence interval, 1.284-3.219). Subgroup analysis showed that OS was significantly worse in the mGPS-1 and mGPS-2 groups than in the mGPS-0 group for all except the following 2 subgroups: localized disease and curative resection.
Conclusions:
The present results show that the mGPS is an independent prognostic factor in patients with PC, especially for advanced-stage disease.
Insights
The modified Glasgow prognostic score (mGPS) effectively predicts survival in pancreatic cancer (PC) patients across all stages. Higher mGPS scores indicate poorer overall survival, establishing it as a key prognostic factor, particularly for advanced disease.
Area of Science:
- Oncology
- Clinical Prognostics
Background:
- The modified Glasgow prognostic score (mGPS) is established for cancer prognosis.
- Previous studies on mGPS in pancreatic cancer (PC) primarily focused on early-stage, surgically treated patients.
Purpose of the Study:
- To evaluate the utility of the mGPS for predicting prognosis in pancreatic cancer patients across all disease stages.
- To analyze mGPS as a prognostic factor in a broad PC cohort using a retrospective design.
Main Methods:
- A retrospective cohort study was conducted.
- Data from 807 pathologically confirmed pancreatic cancer patients were analyzed.
- Patients were categorized by mGPS scores (mGPS-0, mGPS-1, mGPS-2).
Main Results:
- Overall survival (OS) was significantly worse for mGPS-1 (5.8 months) and mGPS-2 (4.8 months) compared to mGPS-0 (15.8 months).
- Both mGPS-1 and mGPS-2 were identified as independent predictors of OS.
- Subgroup analysis revealed worse OS for mGPS-1 and mGPS-2, except in cases of localized disease or curative resection.
Conclusions:
- The modified Glasgow prognostic score (mGPS) is a significant independent prognostic factor for pancreatic cancer.
- mGPS utility is particularly pronounced in patients with advanced-stage pancreatic cancer.
- These findings support the use of mGPS for risk stratification in diverse PC populations.
